There is no single best medicine for Crohn’s disease. The right treatment depends on how severe your inflammation is, where it’s located in your digestive tract, and how your body responds. That said, current guidelines from the American Gastroenterological Association clearly favor starting with advanced therapies (biologics and newer targeted drugs) for moderate-to-severe Crohn’s, rather than working up slowly from milder medications. This represents a significant shift in how gastroenterologists approach treatment.
Why Treatment Depends on Severity
Crohn’s disease exists on a spectrum. Someone with mild inflammation limited to the end of the small intestine has very different treatment needs than someone with deep ulcers throughout their colon. Medications fall into several broad categories, each suited to different situations: aminosalicylates, corticosteroids, immunomodulators, biologics, and targeted synthetic small molecules. Your gastroenterologist will match the intensity of treatment to the intensity of your disease.
For mild Crohn’s disease confined to the lower small intestine (ileal Crohn’s), aminosalicylates like mesalamine can be effective. These drugs work topically, meaning they reduce inflammation right where they make contact with the intestinal lining. Their effectiveness depends heavily on getting the drug to the exact location of your disease, which is why they work better for some patients than others. For mild disease, budesonide, a steroid that acts locally with fewer body-wide side effects than traditional steroids, is another common first option.
The Case for Starting With Biologics Early
For moderate-to-severe Crohn’s, the treatment landscape has changed dramatically. The old approach, called “step-up therapy,” started patients on steroids and milder immune-suppressing drugs, then escalated to biologics only when those failed. The newer “top-down” approach flips this, starting with powerful biologic therapy right away.
The evidence strongly supports starting early. In the PROFILE trial published in The Lancet Gastroenterology & Hepatology, 79% of patients who received early combination biologic therapy achieved sustained steroid-free remission at one year, compared to just 15% of patients on conventional step-up treatment. The early-treatment group also had fewer adverse events, fewer serious complications, and fewer surgeries (one versus ten). This wasn’t a marginal difference. It was a complete reversal of how doctors had been thinking about treatment sequencing.
The AGA now suggests upfront use of advanced therapy over step-up therapy for moderate-to-severe Crohn’s. In practical terms, this means your doctor may recommend a biologic as your first real treatment rather than making you “fail” other drugs first.
Biologics: The Main Options
Biologics are lab-made proteins that target specific parts of the immune system driving inflammation. The AGA recommends several as front-line options for moderate-to-severe disease: infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab, and vedolizumab. These are considered higher-efficacy choices. Certolizumab pegol and upadacitinib (a pill rather than an injection) are also options, though the AGA places them in a slightly lower efficacy tier for patients who haven’t tried biologics before.
These drugs work through different mechanisms. Infliximab and adalimumab block a protein called TNF that drives inflammation. Ustekinumab, risankizumab, mirikizumab, and guselkumab target different inflammatory signals called interleukins. Vedolizumab works by preventing immune cells from migrating into gut tissue. Upadacitinib blocks inflammation through a different pathway entirely, working inside cells rather than outside them.
Head-to-head comparisons between biologics are limited, but the SEAVUE trial found that ustekinumab and adalimumab produced comparable remission rates, with nearly two-thirds of patients in remission at one year. Indirect comparisons between risankizumab and upadacitinib have also shown no statistically significant difference in remission rates during maintenance therapy. In practice, the choice often comes down to your preferences (infusion at a clinic versus self-injection at home versus a daily pill), your other health conditions, and your insurance coverage.
Combination Therapy: More Effective but With Trade-Offs
For some patients, combining a biologic with an immunomodulator drug produces better results than either alone. The evidence is strongest for pairing infliximab with a thiopurine like azathioprine. The immunomodulator helps the biologic work better by improving how the drug moves through your body and reducing the chance your immune system builds antibodies against it.
The trade-off is a higher risk of infections and a small increase in lymphoma risk. A large meta-analysis of over 261,000 patients found that combination therapy carried a lymphoma risk roughly 3.7 times higher than in unexposed patients, compared to about 2.2 times higher for thiopurines alone and 1.5 times for TNF-blockers alone. The absolute risk remains very low, but it’s a real consideration. Some studies also show increased rates of opportunistic infections and herpes zoster reactivation with combination therapy. Your doctor will weigh these risks against the benefit of better disease control, especially if you have aggressive disease.
Steroids: For Flares, Not Long-Term Use
Corticosteroids like prednisone and budesonide are effective at calming active flares but are not maintenance medications. They come with significant side effects when used long-term, including bone loss, weight gain, mood changes, and increased infection risk. A typical course might start at 40 mg of prednisone daily, tapering down over about eight weeks, or 9 mg of budesonide daily for a similar period. Budesonide causes fewer systemic side effects because it’s broken down more quickly by the liver.
The goal of every Crohn’s treatment plan is to get you off steroids and keep you off them. Biologics and immunomodulators serve as the long-term strategy; steroids are the bridge to get inflammation under control while those slower-acting drugs take effect.
What Happens Before Starting a Biologic
Before you begin biologic therapy, your doctor will run several screening tests. Tuberculosis testing is mandatory because these drugs suppress parts of the immune system that keep latent TB in check. You’ll also be tested for hepatitis B, since biologics can cause the virus to reactivate in carriers. A complete blood count, metabolic panel, and skin examination round out the baseline workup. Your doctor will ask about your history of infections, where you’ve lived and traveled, and whether you have conditions like diabetes or heart failure that could affect which drugs are safe for you.
TNF-blocking biologics in particular carry risks of serious infections, reactivation of fungal infections, and rare neurological effects resembling multiple sclerosis. They’re not used in patients with moderate-to-severe heart failure. These risks sound alarming in a list, but for most patients with active Crohn’s, the danger of uncontrolled inflammation, which can lead to strictures, fistulas, and surgery, outweighs the medication risks.
Biosimilars Can Lower Costs
If cost or insurance coverage is a barrier, biosimilars offer a meaningful alternative. Biosimilars are near-identical copies of biologic drugs that have lost patent exclusivity. Multiple biosimilars are now available for infliximab (including Inflectra, Renflexis, and Avsola) and adalimumab (including Amjevita, Cyltezo, Hyrimoz, Hadlima, and others). These have the same efficacy and safety profiles as their reference drugs but typically cost less. If your doctor prescribes a biologic, it’s worth asking whether a biosimilar version is available on your insurance plan.
Choosing the Right Treatment
The “best” Crohn’s medication is ultimately the one that gets your disease into deep remission, keeps you off steroids, and fits your life. For mild ileal disease, a topical anti-inflammatory may be enough. For moderate-to-severe disease, the evidence increasingly points toward early, aggressive treatment with biologics, potentially combined with an immunomodulator, as the strategy most likely to prevent complications and surgery down the road. The specific biologic matters less than starting one promptly and monitoring your response with regular lab work and imaging.
Crohn’s treatment is also not static. If one medication stops working or causes side effects, switching to a drug with a different mechanism is a well-established strategy. Having multiple effective drug classes available means that losing response to one therapy doesn’t mean running out of options.